Leukotrienes (LTs) are a family of inflammatory mediators derived from arachidonic acid. HepaRG cultures as determined using LC-MS/MS analysis, though the modified sinapoyl ketone (10) retained 50% of its inhibitory activity after up to one hour of incubation. This study has identified at least one CAPE analogue, compound 10, that shows favorable properties that warrant further in vivo investigation as an antiinflammatory compound.
Although inflammation is a defense mechanism vital to health, it also contributes to the development and progression of many chronic diseases. [8] [9] [10] [11] 5-LO and leukotrienes are intimately involved in the progression of inflammatory diseases like asthma, atherosclerosis and rheumatoid arthritis. [12] [13] [14] [15] Several key proteins associated with LT biosynthesis and action, including 5-LO, have been investigated and validated as antiinflammatory targets. 16 To date, zileuton (1) (Zyflo ® ) ( Figure 1 ) is the only drug which targets the leukotriene pathway through the inhibition of 5-LO and is clinically approved in the United States for the chronic treatment of asthma. 17 However, its use is limited due to hepatic side effects and an unfavorable pharmacokinetic profile. [18] [19] [20] Hence the pursuit of new compounds targeting 5-LO and the LT pathway remains an active area of research and clinical development. 21 Several natural compounds have been investigated as potential 5-LO inhibitors. Among these is caffeic acid phenethyl ester (CAPE) (2) ( Figure 1 ), a bioactive component of honeybee propolis 22 that has been reported to have beneficial health properties, including antiinflammatory activity. [23] [24] [25] [26] Of importance, CAPE (2) inhibits LT biosynthesis in isolated human neutrophils with an IC 50 (0.5 µmol/L) that is lower than that of zileuton (1) and that is similar (1.8 µmol/L) to that of zileuton (1) in whole blood. 27, 28 This suggests that while remaining a potent inhibitor of LT biosynthesis, the susceptibility of CAPE (2) to modifications such as hydrolysis by esterases may reduce its potency in a physiological setting since caffeic acid itself is a poor 5-LO inhibitor. 27 Several analogues of CAPE (2) have been developed based on modifications of the caffeic moiety or of the ester linkage, and some have shown improved inhibition of leukotriene biosynthesis. 27, 29, 30 In this study, CAPE (2) analogues in which the catechol moiety was modified and/or the ester bond was replaced with a ketone were investigated for their impact on the inhibition of leukotriene biosynthesis in human neutrophils and whole blood. Additionally, the stability of the compounds was evaluated in whole blood and in the human hepatocyte HepaRG cell model, and metabolites were identified using liquid chromatography-mass spectrometry (LC-MS/MS). In summary, sinapic acid and 2,5-dihydroxy derivatives displayed a better inhibitory activity than caffeic acid derivatives and the ketone analogues displayed superior inhibition and stability. All compounds were modified by glucuronidation, however, the glucuronidated sinapic acid ketone analogue retained significant inhibitory activity.
| ME THODS

| Synthesis of CAPE-like analogues
Ester and ketone analogues of CAPE (2) were synthesized by one pot esterification or an aldol condensation, respectively, as previously reported. After 14 days, the culture medium was replaced by the same formulation as above supplemented with 2% dimethyl sulfoxide (DMSO) to induce differentiation. Cells were considered differentiated and ready for experiments after 14 days of differentiation (28 days after seeding). Cells were then stimulated for 15 minutes at 37°C with the addition of 10 µmol/L calcium ionophore A23187 (Sigma-Aldrich) and 10 µmol/L arachidonic acid (Cayman Chemical). 28 Stimulations were stopped by adding 0.5 volume of cold CH 3 OH:CH 3 CN (1:1) containing 100 ng/mL of prostaglandin B 2 (PGB 2 ) as internal standard.
| HEK293 cell stimulation and measurement of 5-LO products
Samples were stored at −20°C and analyzed for 5-LO products using reversed-phase high-performance liquid chromatography (RP-HPLC) as described previously. 
| Isolation and stimulation of polymorphonuclear leukocytes
Heparinized blood (see Ethics statement) was collected, centrifuged at 200g for 10 minutes to collect plasma, and erythrocytes were sedimented in dextran. PMNL were obtained after centrifugation on a lymphocyte separation medium cushion (density, 1.077 g/mL)
(Wisent) at 900 g for 20 minutes, followed by hypotonic lysis to remove residual erythrocytes. 33 PMNL were counted and resuspended at 10 7 cells/mL in HBSS supplemented with 1.6 mmol/L CaCl 2 and 0.3 U/mL adenosine deaminase (Sigma-Aldrich). PMNL were preincubated with the test compounds or their diluent (0.1% DMSO) for 5 minutes at 37°C and were then stimulated with 1 µmol/L thapsigargin (Sigma-Aldrich) for 15 minutes at 37°C. 27 Reactions were stopped by adding two volumes of CH 3 OH:CH 3 CN (1:1) containing the internal standard PGB 2 (100 ng/mL), and samples were processed for RP-HPLC analysis of 5-LO products. F I G U R E 1 Structures of Zileuton (1) and CAPE (2) In some experiments, platelets were removed from plasma by centrifugation at 2000g for 20 minutes, and test compounds were incubated in plasma for up to 60 minutes prior to addition to PMNL suspensions for subsequent stimulation and detection of 5-LO products as described above.
| Ex vivo whole blood stimulation
Blood was collected in tubes containing heparin as anticoagulant.
Test compounds or their diluent control (DMSO, 0.1%) were added to 1 mL of heparinized blood at the indicated concentrations and incubated for 5 minutes in a water bath at 37°C. Stimulation was initiated with the addition of 125 μL of 40 mg/mL of opsonized zymosan, samples were then gently vortexed and incubated at 37°C for 30 minutes. 34 Samples were then centrifuged at 960g for 10 minutes at 4°C, plasma was removed and added to tubes containing 4 volumes of CH 3 OH:CH 3 CN (1:1) containing 100 ng/mL of PGB 2 as internal standard. Samples were stored overnight at −20°C, and then centrifuged at 3300g for 10 minutes. Samples were then purified on C18 cartridges, were eluted with CH 3 OH, dried under nitrogen, resuspended in 46% of CH 3 OH:CH 3 CN (1:1), and analyzed using RP-HPLC as described above.
In some experiments, test compounds were incubated in blood for up to 120 minutes prior to stimulation with opsonized zymosan and detection of 5-LO products as described above. 
| Incubation of test compounds with HepaRG cells
| Docking
Docking of all inhibitors into the active site of the crystal structures of human 5-LO (PDB code: 3O8Y, 2.39 A resolution) 35 as well as the calculations of the affinities of the test molecules was performed with the AutoDock vina. 
| Statistics
Statistical analysis and graph design were performed with 
| RE SULTS
| Biosynthesis of 5-LO products
Elimination of the catechol or modifications of the functional groups on the caffeic moiety of CAPE has resulted in compounds that poorly inhibit LT biosynthesis, 27, 29 with the exception of the sinapic acid (2,4-dimethoxy, 3-hydroxy) derivative that results in better inhibitory activity than CAPE (2). 29 Therefore, a first series of experi- (B) (A) 10) ( Figure 3A ) was also synthesized and tested for inhibitory activity. All six test compounds showed a significant inhibition of LT biosynthesis in human PMNL, with compounds 5, 7 and 10 showing a near complete inhibition at the tested concentration ( Figure 3B ).
Since all six selected test compounds showed significant inhibition at a concentration of 1 μmol/L, the compounds were screened further in concentration-response studies to better characterize their relative inhibitory capacities in stimulated PMNL and in whole blood ( Table 1 In PMNL, all compounds outperformed CAPE (2) and possessed IC 50 values that were significantly lower than the clinically approved 5-LO inhibitor Zileuton (1). However, in whole blood, although Zileuton (1) had a lower IC 50 value than CAPE (2), compounds 7 and 9 were similar to zileuton, while compounds 5, 8 and 10 all showed lower IC 50 values than zileuton.
| Molecular docking
Docking of all inhibitors into the active site of the crystal structures of human 5-LO (PDB code: 3O8Y, 2.39 A resolution) 35 was performed with AutoDock Vina. As shown in Table 2 Compound 7 (−8.9 kcal/mol) underwent pi-pi interactions with
His367 and was the only tested ligand that showed a π-π interaction with Phe177 which may play a part in product specificity. other. Compounds 9 and 10 were partially superimposed on the substituted ring but they differed after the double bond in the connecting chain due the greater flexibility allowed by the missing ester group which is substituted by a carbonyl group in compound 10.
| In silico physicochemical properties and druglikeness evaluation
The physicochemical properties of the selected compounds were evaluated to determine if they are within the Lipinski's Rule of Five, which is important for pharmacokinetics and drug development.
For this purpose, physicochemical and ADME (absorption, distribution, metabolism, and excretion) properties were calculated using the SwissADME (a free web tool to evaluate pharmacokinetics, druglikeness and medicinal chemistry friendliness of small molecules) ( 
| Stability of test compounds in plasma and whole blood
The stability of the inhibitory activity of the test compounds was evaluated in human plasma and in whole blood. Firstly, compounds were incubated at 37°C for various times in human plasma and were then evaluated for their ability to inhibit the stimulated biosynthesis of 5-LO products in human PMNL. Figure 4A shows that all compounds had a steady inhibitory effect over time which suggests that the compounds are stable in plasma. A second series of experiments was performed in whole blood by incubating the test compounds or their diluent (DMSO 0.1%) for various times in whole blood prior to stimulation with zymosan. Unlike human plasma results, the inhibitory effect of CAPE (2) and compound 7, the two compounds with catechol groups, decreased over time with a complete loss of inhibitory activity after 240 minutes of incubation ( Figure 4B ). The inhibitory activity of all other compounds remained quite stable over 
| Stability of test compounds in HepaRG cell culture
HepaRG cells can be differentiated into hepatocytes and biliary-like epithelial cells and maintain liver functions such as expression of drug metabolizing enzymes and transporters. 43, 44 Therefore, this is a valuable in vitro model to assess the potential hepatic stability of experimental compounds. To study the kinetics of test compound stability and its effects on the biosynthesis of LTB 4 , the test compounds were incubated with HepaRG cells and the culture medium was then collected at different times to measure their remaining presence and the residual capacity to inhibit the biosynthesis of 5-LO products.
Based on the relative peak area for each compound compared to unmetabolized starting material (t = 0) following separation by HPLC, peaks associated with all three ester-linked compounds 2, 5 and 9 disappeared from HLPC chromatograms more quickly ( Figure 5A ) and exhibited shorter half-lives ( Figure 5B ) than their ketone counterparts. The sinapic acid ketone analogue 10 had a significantly greater half-life than all other analogues.
The loss of inhibitory activity of the test compounds ( Figure 6) followed a similar pattern to that of their disappearance from the cell culture medium. After 15 minutes most compounds lost some inhibitory activity against 5-LO product biosynthesis, although the loss of biological activity was not as apparent as the loss of peak height seen in Figure 5 . After 60 minutes CAPE (2), compounds 7, 5, 8 and 9 had lost all their inhibitory activity ( Figure 6 ). However, compound 10 lost its inhibitory activity much more slowly over time and maintained significant inhibition of the biosynthesis of 5-LO products after 60 minutes despite its complete disappearance from culture medium as shown in Figure 5 . The comparator compound zileuton inhibited the 5-LO product biosynthesis in a steady manner over time.
| Identification of metabolites following incubation of test compounds in HepaRG cell culture
The goal of the next set of experiments was to identify using LC-MS/ MS the metabolites formed following incubation with HepaRG cells. Abbreviations: BBBP, blood brain barrier permeation; CLog Po/w, logarithm of compound partition coefficient between n-octanol and water; GIA, gastrointestinal absorption; HBA, hydrogen bond acceptors; HBD, hydrogen bond donors; MW, molecular weight; n, number; ROTB, rotatable bonds; TPSA, topological polar surface area.
Firstly, the retention time and fragmentation pattern were determined using negative ion and positive ion LC-MS/MS for each test compound prior to incubation with cells. Table S1 shows that the expected mass for each compound was obtained using LC-MS and also
shows the mass of the fragments obtained and the HPLC retention times. HepaRG cells were then incubated in the presence of each test compound for 7.5 and 60 minutes at 37°C and the supernatants were analyzed using LC-MS/MS. Figure 7A shows the negative ion LC-MS analysis of CAPE (2) following incubation with HepaRG cells for 7.5 and 60 minutes. At 7.5 minutes, the total ion chromatogram (TIC) shows one peak that corresponds to the retention time and mass of CAPE (m/z-283), however after 60 minutes a second peak appears with m/z-459.
Single ion monitoring (SIM) of the second peak shows that the compound with m/z-459 was also present at 7.5 minutes. The frag-
mentation of this second peak by MS/MS shows a fragment with a mass of [M-H-176]
− that corresponds to the expected mass of glucuronic acid. A similar profile was also seen for the ketone analogue of CAPE (2), compound 7 ( Figure 7B ). The results of the mass spectral analyses of all test compounds are summarized in Table S1B .
Additionally, the presence of [M + H 2 -H] + ions seen in Figure 7B suggests the hydrogenation of a double bond. In fact, this pattern was observed for all ketone compounds 7, 8 and 10 that had been incubated with HepaRG cells but not for their respective esters. The SIM chromatograms obtained with the respective metabolite's mass and that of the M + H 2 ions show that the peaks are resolved for compounds 8 and 10, but not 7 ( Figure 7C ). This suggests that these compounds undergo α,β-unsaturated ketone reduction in these culture conditions. Based on the relative peak areas, a significant proportion of the molecules undergo hydrogenation.
| D ISCUSS I ON
5-Lipoxygenase and its products, the leukotrienes, are intimately involved in the inflammatory response and have been targeted for the treatment of asthma for over two decades with the development of the 5-LO inhibitor zileuton (Zyflo ® ) and the cys-leukotriene-1 (Cys-LT1) receptor antagonists montelukast (Singulair  ® ) and zafirlukast (Accolate ® ). More recently, 5-LO has been identified as a potential therapeutic target for conditions such as rheumatoid arthritis, 45, 46 atherosclerosis, [47] [48] [49] Alzheimer's disease 50 and leukemia stem cells. 51, 52 However, zileuton has poor pharmacokinetic properties and liver toxicity issues, whereas the Cys-LT1 receptor antagonists only target the cys-LTs and not the LTB 4 receptors that play an important role in several pathologies.
Therefore, there is interest for the development of effective 5-LO inhibitors. 21 In this study, analogues of the natural polyphenolic compound CAPE (2) were synthesized and evaluated as 5-LO inhibitors. CAPE is a potent 5-LO inhibitor with IC 50 values in the high nmol/L to low μmol/L range in isolated human neutrophils and in whole human blood, respectively. 27 However, its stability as a drug candidate has been questioned partly because of its susceptibility to esterases 53 that catalyze its hydrolysis to the much less active caffeic acid. 27 The analogues described in this study include ketones that are not susceptible to esterase action, as well as analogues of the caffeoyl moiety of the molecule that show enhanced inhibitory activity toward the biosynthesis of 5-LO products. Some of these analogues were shown to be more resistant to degradation and to loss of inhibitory activity following incubation in HepaRG cell culture and in whole human blood.
With regard to the caffeoyl moiety of CAPE (2), it was previously shown that cinnamic acid phenethyl ester, devoid of the vicinal hydroxyl groups, and various monohydroxy derivatives of CAPE (2) do not inhibit LT biosynthesis at concentrations up to 10 µmol/L. 27, 29 Similarly, mono, di-and tri-methoxy derivatives of CAPE (2) are also without inhibitory activity. 29 The only other substitution previously tested that results in inhibitory activity similar to or better than CAPE (2) was the sinapic acid (3,5-dimethoxy, 4-hydroxy) derivative, compound 9. 29 This study provides additional information regarding the impact of substitutions on the caffeoyl moiety. Unlike CAPE (2), the 2,4-dihydroxy and the 3,5-dihydroxy compounds 4 and 6, respectively, were without inhibitory activity at the tested concentrations, whereas the 2,5-dihydroxy compound 5 showed superior inhibition of 5-LO product biosynthesis compared to CAPE (2) in isolated PMNL and in whole blood. In fact, compound 5 was equivalent to the sinapic acid derivative 9 in isolated PMNL and showed superior inhibition in whole blood. Therefore, the position of the hydroxyl groups on the phenol is critical to the capacity to inhibit 5-LO product biosynthesis. and whole blood, previous studies showed that CAPE (2) is rapidly hydrolyzed to caffeic acid in rat plasma (but not in human plasma)
by a carboxylesterase, and oral administration to rats also results in excretion of caffeic acid as the major metabolite in the urine. [53] [54] [55] Since an effective drug candidate should not be enzymatically labile in plasma, CAPE analogues were synthesized with structural modifications of the ester bond. It was previously shown that an amide analogue of CAPE inhibited LT biosynthesis and 5-LO activity, though with reduced potency compared to CAPE. 27 However, ketone derivatives of CAPE (2) have shown inhibition of 5-LO product biosynthesis in human PMNL that appear to be superior to that of CAPE (2). 37 Therefore, ketone derivatives of the most effective esters were synthesized with the speculation that they should be more potent and more stable than their ester analogues.
As expected, the ketone derivatives of CAPE (2) were generally as good or better inhibitors of 5-LO product biosynthesis as their ester analogues in both isolated PMNL and whole blood in short-term incubations. However, although the inhibitory capacity of all compounds appeared to be stable in plasma, only CAPE (2) and compound 7 rapidly lost their ability to inhibit leukotriene All tested compounds showed favorable physicochemical and ADME properties that are compatible with favorable pharmacokinetic and drug-likeness properties, as well as characteristics that are consistent with oral bioavailability. Indeed, all compounds adhered to Lipinski's rule of 5 indicating that they do not trigger a computational alert for absorption or permeation that would suggest poor bioavailability. 40 Compounds that trigger the alert are likely to be troublesome in subsequent in vivo studies. In a preliminary evaluation of the molecular interactions between selected compounds and 5-lipoxygenase, all compounds showed a stronger affinity to 5-LO than zileuton. Furthermore, several interactions were identified that are consistent with the inhibition of enzyme activity such as interactions with His 600 that may be necessary for the positioning of the arachidonic acid substrate (compounds 5 and 8), π-π interactions with Phe177 (compound 7) which may play role in product specificity 39 and π-π interactions with His 372 (CAPE (2), 5, 9, 8 and 10) that suggest a good position to coordinate the iron atom or, at a minimum, block some access to the binding site cavity.
Although CAPE has been shown to be an excellent inhibitor of 5-LO product biosynthesis, a series of structure-activity relationship studies were undertaken to develop new compounds that possess enhanced biological activity. [27] [28] [29] [30] 37 Predicting the best performing analogues has not been apparent. For example, the relation between the presence and position of dihydroxy groups or methoxy groups and inhibitory activity is critical but was not predictable. Similarly, different structural analogues of the ester moiety show significantly different inhibitory activity, and possessing radical scavenging activity comparable to that of CAPE does not translate into good 5-LO inhibition. Amongst the numerous CAPE analogues that have been evaluated, the 2,5-dihydroxy compounds (5 and 8) and the sinapic acid derivatives (9 and 10) described in this study are those that have shown the best inhibitory activity in isolated PMN and in whole blood. This study was the first to evaluate the biological stability of these analogues. While ketone derivatives showed better stability than esters, sinapic acid phenethyl ketone (10) showed the longest half-life and was the only molecule that maintained inhibitory activity in hepatocyte cultures. Overall, the excellent inhibition of 5-LO product biosynthesis in a complex matrix combined with its better stability and favorable physicochemical and ADME properties suggest that compound 10 is a good candidate for continued development in preclinical models of inflammatory diseases.
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